To investigate the efficacy and safety of diquafosol ophthalmic solution on cGVHD dry eye
Conditions
Interventions
diquafosol ophthalmic solution, vitamin a ophthalmic solution, sodium hyaluronate ophthalmic solution
artifical tears vitamin a ophthalmic solution sodium hyaluronate ophthalmic solution
Sponsors
Department of Ophthalmology, Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: newly diagnosed dry eye patients after hematopoietic stem cell transplantation dry eye syndrome severity level 1-3 (dry eye workshop classiification 2007)
Exclusion criteria
Exclusion criteria: dry eye syndrome severity level 4 (dry eye workshop classification 2007) patients having fear of dry eye syndrome progression, such as having graft-vs-host disease in other organs patients with sjogren's syndrome, ocular cicatricial pemphigoid, or stevens-johnson syndrome history of ophthalmic surgery contact lens wearers patients who will undergo radiotherapy during the testing period topical or oral administration of cevimeline hydrochloride hemihydrate, pilocarpine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom Tear film breakup time Schirmer test Fluorescein staining Rosebengal staining Corneal sensitivity | — |
Secondary
| Measure | Time frame |
|---|---|
| Impression cytology Brush cytology Biopsy | — |
Countries
Japan
Contacts
Public ContactYoko Ogawa
Keio University School of Medicine Department of Ophthalmology
Outcome results
None listed